日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer

DCZ5248 是一种新型 Hsp90 和自噬双重抑制剂,对结肠癌具有抗肿瘤活性

Xiang-Ling Chen, Peng Liu, Wei-Liang Zhu, Li-Guang Lou

SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models

SHR-A1403 是一种新型 c-Met 抗体-药物偶联物,在 c-Met 过表达模型中发挥令人鼓舞的抗肿瘤活性

Chang-Yong Yang #, Lei Wang #, Xing Sun, Mi Tang, Hai-Tian Quan, Lian-Shan Zhang, Li-Guang Lou, Shao-Hua Gou

Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma

核糖体蛋白 S6 磷酸化的异常调节导致 BRAF 突变黑色素瘤对 MAPK 通路抑制剂产生获得性耐药性

Ming-Zhao Gao, Hong-Bin Wang, Xiang-Ling Chen, Wen-Ting Cao, Li Fu, Yun Li, Hai-Tian Quan, Cheng-Ying Xie, Li-Guang Lou

Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species

口服酪氨酸激酶抑制剂安罗替尼在实验动物体内的药代动力学和分布

Chen-Chun Zhong, Feng Chen, Jun-Ling Yang, Wei-Wei Jia, Li Li, Chen Cheng, Fei-Fei Du, Su-Ping Zhang, Cheng-Ying Xie, Na-Ting Zhang, Olajide E Olaleye, Feng-Qing Wang, Fang Xu, Li-Guang Lou, Dong-Ying Chen, Wei Niu, Chuan Li

Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro

姜黄素衍生物 C817 体外抑制伊马替尼耐药慢性粒细胞白血病细胞与野生型或突变型 Bcr-Abl 的增殖

Li-xian Wu, Ying Wu, Rui-jia Chen, Yang Liu, Li-sen Huang, Li-guang Lou, Zhi-hong Zheng, Yuan-zhong Chen, Jian-hua Xu